Mexico’s government said four pharmaceutical companies will invest more than 12,000 million pesos (about US$643 million) to expand manufacturing and research operations in the country, bolstering the administration’s industrial push known as Plan México. At President Claudia Sheinbaum’s 7 August morning news conference, Health Secretary David Kershenobich and Economy Secretary Marcelo Ebrard detailed the commitments: Boehringer Ingelheim will put 3,500 million pesos into transforming its Xochimilco site into the world’s largest tablet plant; Carnot Laboratorios will invest a similar sum to build a new complex in Hidalgo; Bayer will spend 3,000 million pesos upgrading facilities in Veracruz, Estado de México and Tlaxcala; and AstraZeneca will allocate just over 2 billion pesos to expand research, digital capabilities and production in Estado de México. The projects, scheduled to roll out over the next five years, are expected to create about 3,000 direct jobs and as many as 22,000 indirect positions across Ciudad de México, Jalisco and other states. Officials said the investment will deepen local supply chains, support advanced therapies and strengthen Mexico’s health sovereignty ahead of future pandemic risks.